| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Franjo Grotenherme. Cannabinoids. Current drug targets. CNS and neurological disorders. vol 4. issue 5. 2006-01-23. PMID:16266285. |
besides phytocannabinoids of the cannabis plant, modulators of the cannabinoid system comprise synthetic agonists and antagonists at the cb receptors and inhibitors of endocannabinoid degradation. |
2006-01-23 |
2023-08-12 |
Not clear |
| Raphael Mechoula. Plant cannabinoids: a neglected pharmacological treasure trove. British journal of pharmacology. vol 146. issue 7. 2006-01-20. PMID:16205721. |
most of the cannabinoids in cannabis sativa l. have not been fully evaluated for their pharmacological activity. |
2006-01-20 |
2023-08-12 |
Not clear |
| Jenny L Wiley, James J Burston, Darnica C Leggett, Olga O Alekseeva, Raj K Razdan, Anu Mahadevan, Billy R Marti. CB1 cannabinoid receptor-mediated modulation of food intake in mice. British journal of pharmacology. vol 145. issue 3. 2006-01-13. PMID:15778743. |
the cb(2) cannabinoid receptor antagonist sr144528 and the nonpsychoactive cannabinoid cannabidiol did not affect food intake nor activity. |
2006-01-13 |
2023-08-12 |
mouse |
| Mark Weiser, Shlomo No. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues in clinical neuroscience. vol 7. issue 1. 2006-01-13. PMID:16060598. |
others reported higher levels of endogenous cannabinoids in the blood and cerebrospinal fluid of patients; these findings were independent of possible cannabis use. |
2006-01-13 |
2023-08-12 |
Not clear |
| T C Kirkha. Endocannabinoids in the regulation of appetite and body weight. Behavioural pharmacology. vol 16. issue 5-6. 2006-01-09. PMID:16148436. |
with the identification of endogenous agonists, such as anandamide, scientists have sought to uncover the biological role of endocannabinoid systems; initially guided by the long-established actions of cannabis and exogenous cannabinoids such as delta9-tetrahydrocannabinol (thc). |
2006-01-09 |
2023-08-12 |
Not clear |
| A B Ilan, A Gevins, M Coleman, M A ElSohly, H de Wi. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behavioural pharmacology. vol 16. issue 5-6. 2006-01-09. PMID:16148455. |
neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. |
2006-01-09 |
2023-08-12 |
human |
| A B Ilan, A Gevins, M Coleman, M A ElSohly, H de Wi. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behavioural pharmacology. vol 16. issue 5-6. 2006-01-09. PMID:16148455. |
this study investigated the contribution of different cannabinoids to the subjective, behavioral and neurophysiological effects of smoked marijuana. |
2006-01-09 |
2023-08-12 |
human |
| A B Ilan, A Gevins, M Coleman, M A ElSohly, H de Wi. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behavioural pharmacology. vol 16. issue 5-6. 2006-01-09. PMID:16148455. |
in the four sessions under blinded conditions subjects smoked marijuana cigarettes containing placebo (no active cannabinoids), or cigarettes containing thc with low or high levels of cannabichromene (cbc; 0.1% versus 0.5%) and low or high levels of cannabidiol (cbd; 0.2% versus 1.0%). |
2006-01-09 |
2023-08-12 |
human |
| Guillermo Velasco, Ismael Galve-Roperh, Cristina Sánchez, Cristina Blázquez, Amador Haro, Manuel Guzmá. Cannabinoids and ceramide: two lipids acting hand-by-hand. Life sciences. vol 77. issue 14. 2006-01-05. PMID:15958274. |
cannabinoids, the active components of cannabis sativa (marijuana) and their endogenous counterparts, exert their effects by binding to specific g-protein-coupled receptors that modulate adenylyl cyclase and ion channels. |
2006-01-05 |
2023-08-12 |
Not clear |
| Patrick Weydt, Soyon Hong, Anke Witting, Thomas Möller, Nephi Stella, Michel Klio. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. vol 6. issue 3. 2006-01-04. PMID:16183560. |
emerging evidence from clinical studies and transgenic mouse models of als suggests that cannabinoids, the bioactive ingredients of marijuana (cannabis sativa) might have some therapeutic benefit in this disease. |
2006-01-04 |
2023-08-12 |
mouse |
| Patrick Weydt, Soyon Hong, Anke Witting, Thomas Möller, Nephi Stella, Michel Klio. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. vol 6. issue 3. 2006-01-04. PMID:16183560. |
however, delta(9)-tetrahydrocannabinol (delta(9)-thc), the predominant cannabinoid in marijuana, induces mind-altering effects and is partially addictive, compromising its clinical usefulness. |
2006-01-04 |
2023-08-12 |
mouse |
| Mahmoud A Elsohly, Desmond Slad. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life sciences. vol 78. issue 5. 2005-12-22. PMID:16199061. |
chemical constituents of marijuana: the complex mixture of natural cannabinoids. |
2005-12-22 |
2023-08-12 |
human |
| Ganesh A Thakur, Richard I Duclos, Alexandros Makriyanni. Natural cannabinoids: templates for drug discovery. Life sciences. vol 78. issue 5. 2005-12-22. PMID:16242157. |
recent studies have elucidated the biosynthetic pathway of cannabinoids and have highlighted the preference for a c-3 n-pentyl side chain in the most prominently represented cannabinoids from cannabis sativa and their medicinally important decarboxylation products. |
2005-12-22 |
2023-08-12 |
Not clear |
| Ganesh A Thakur, Richard I Duclos, Alexandros Makriyanni. Natural cannabinoids: templates for drug discovery. Life sciences. vol 78. issue 5. 2005-12-22. PMID:16242157. |
structure-activity relationship (sar) studies performed on delta(9)-tetrahydrocannabinol (delta(9)-thc), the key psychoactive ingredient of cannabis, and its synthetic analogues have identified the c-3 side chain as the key pharmacophore for ligand affinity and selectivity for the known cannabinoid receptors and for pharmacological potency. |
2005-12-22 |
2023-08-12 |
Not clear |
| Maciej Kochanowski, Maria Kał. Tetrahydrocannabinols in clinical and forensic toxicology. Przeglad lekarski. vol 62. issue 6. 2005-12-21. PMID:16225128. |
cannabinoids are the natural constituents of marihuana (cannabis). |
2005-12-21 |
2023-08-12 |
human |
| Rebecka Coles, Thomas T Clements, Gordon J Nelson, Gwendolyn A McMillin, Francis M Urr. Simultaneous analysis of the Delta9-THC metabolites 11-nor-9-carboxy-Delta9-THC and 11-hydroxy-Delta9-THC in meconium by GC-MS. Journal of analytical toxicology. vol 29. issue 6. 2005-12-09. PMID:16168173. |
the analysis of 246 cannabinoid screen positive specimens illustrated the importance of including the 11-hydroxy-thc in a meconium marijuana confirmation: 16 specimens confirmed positive for 11-hydroxy-thc only, resulting in a 6.5% increase in the positivity rate compared to 9-carboxy-thc alone. |
2005-12-09 |
2023-08-12 |
Not clear |
| Mario van der Stelt, Vincenzo Di Marz. Cannabinoid receptors and their role in neuroprotection. Neuromolecular medicine. vol 7. issue 1-2. 2005-12-08. PMID:16052037. |
two g protein-coupled receptors for marijuana's psychoactive component, delta9-tetrahydrocannabinol, have been cloned to date, the cannabinoid cb1 and cb2 receptors. |
2005-12-08 |
2023-08-12 |
Not clear |
| Natalia Battista, Filomena Fezza, Mauro Maccarron. Endocannabinoids and their involvement in the neurovascular system. Current neurovascular research. vol 1. issue 2. 2005-12-05. PMID:16185189. |
anandamide (n-arachidonoylethanolamine; aea) and 2-arachidonoylglycerol are the main endogenous agonists of cannabinoid receptors, able to mimic several pharmacological effects of delta(9)-tetrahydrocannabinol, the active principle of cannabis sativa preparations like hashish and marijuana. |
2005-12-05 |
2023-08-12 |
Not clear |
| J Ludovic Croxford, Kegiang Wang, Stephen D Miller, David M Engman, Kevin M Tyle. Effects of cannabinoid treatment on Chagas disease pathogenesis: balancing inhibition of parasite invasion and immunosuppression. Cellular microbiology. vol 7. issue 11. 2005-11-29. PMID:16207246. |
refined use of cannabinoids may prove therapeutic in the future, but our results raise concern about the effect of cannabis use on those chronically infected by t. cruzi and on heart cell homeostasis generally. |
2005-11-29 |
2023-08-12 |
mouse |
| Robert Melamed. Cannabis and tobacco smoke are not equally carcinogenic. Harm reduction journal. vol 2. 2005-11-08. PMID:16232311. |
cannabis smoke contains cannabinoids whereas tobacco smoke contains nicotine. |
2005-11-08 |
2023-08-12 |
Not clear |